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A b s t r a c t
Anxiety disorders are a serious problem in both
psychiatric practice and research, affecting about 20%
of the general population. This paper highlights the
problem of interactions between quality of treatment
compliance and the course of anxiety disorders, as well
as the outcomes of therapy.
There is a general scarcity of data concerning compliance
in anxiety disorders, and coherence of the available
evidence is not a rule. Everyday clinical experience
suggests that compliance among patients with anxiety
disorders is generally satisfactory (the validity of this
statement is supported by the results of some trials), but
some data indicate that up to 50% of patients belonging
to this group are at risk of treatment drop-out. Drop-
out rates are higher among people receiving psycho -
therapy in outpatient settings than among inpatients.
Published evidence indicates that the quality of
compliance is positively correlated with the outcomes
of cognitive-behavioural therapy of panic disorder; the
analogous data regarding obsessive-compulsive disorder,
social anxiety disorder and generalized anxiety disorder
are unclear. Various authors advocate psychoeducation
(regardless of the type of disorder) as the best way of
enhancing compliance, as ‘knowledge is an important
factor in change’.
Compliance with antidepressant treatment seems to be
unsatisfactory. Side effects are the most frequent reason
for discontinuing or switching antidepressants. Patients
with comorbid depressive disorders seem to be more
compliant with pharmacotherapy.
Key words: anxiety disorders, compliance, psycho -
therapy, pharmacotherapy.
S t r e s z c z e n i e
Zaburzenia lękowe są istotnym problemem zarówno
w psychiatrycznej praktyce klinicznej, jak i w badaniach
naukowych. Występują one u ok. 20% osób w popula-
cji ogólnej. Autorzy niniejszej pracy przedstawiają zagad-
nienie relacji między jakością współpracy w leczeniu
a przebiegiem zaburzeń lękowych oraz wynikami tera-
pii osób cierpiących z ich powodu.
Opublikowano bardzo niewiele danych dotyczących
współpracy w leczeniu chorych z zaburzeniami lękowy-
mi, a dostępne informacje nie zawsze są spójne. Wpraw-
dzie doświadczenie kliniczne podpowiada, że jakość
współpracy w terapii osób należących do omawianej gru-
py jest zwykle zadowalająca (a opinia ta znajduje
potwierdzenie w wynikach niektórych badań), ale rezul-
taty niektórych analiz wskazują, iż ryzyko przedwczes -
nej rezygnacji z leczenia może dotyczyć nawet 50% cho-
rych z zaburzeniami lękowymi. Wskaźniki rezygnacji
z leczenia są większe wśród osób korzystających z psy-
choterapii w trybie ambulatoryjnym niż w ramach hospi-
talizacji. Dostępne przesłanki świadczą o tym, że jakość
współpracy w leczeniu dodatnio koreluje z wynikami
terapii poznawczo-behawioralnej stosowanej u chorych
z zaburzeniem panicznym. Analogiczne dane dotyczą-
ce leczenia zaburzenia obsesyjno-kompulsyjnego, zespołu
lęku społecznego lub zaburzenia lękowego uogól nio-
nego są niejednoznaczne. Wielu autorów zaleca stoso-
wanie psychoedukacji (niezależnie od rodzaju zaburze-
nia lękowego) jako najlepszej metody poprawiania
jakości współpracy w leczeniu, gdyż „wiedza jest istot-
nym czynnikiem zmiany”.
Jakość współpracy w leczeniu odnośnie do stosowania
leków przeciwdepresyjnych jest raczej niezadowalająca.
Występowanie działań niepożądanych jest najczęstszą
przyczyną rezygnacji z przyjmowania tych związków lub
zmiany leków w tej grupie. Wydaje się, że chorzy ze
współistniejącymi zaburzeniami depresyjnymi lepiej
współpracują w leczeniu farmakologicznym. 
Słowa kluczowe: zaburzenia lękowe, współpraca
w leczeniu, psychoterapia, farmakoterapia.
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Introduction
Anxiety disorders are a serious problem in
both psychiatric practice and research. Accord-
ing to the recent epidemiological data, as many
as about 20% of the general population may be
affected by this group of psychiatric disorders
(Leray et al. 2011). Furthermore, high rates of
comorbidity between anxiety disorders and oth-
er psychiatric or medical problems is a rule
rather than the exception (Jaeschke et al. 2010).
Given these facts, it would be justified to say
that this group of disorders should be seen as
one of the most significant issues in contempo-
rary psychiatry.
This paper highlights the problem of inter-
actions between quality of compliance and the
course of anxiety disorders, as well as the treat-
ment outcomes.
Non-compliance among psychiatric
patients – general considerations
Both epidemiological and clinical data sug-
gest that various forms of non-compliance are
among the major (if not the most important)
obstacles to success in psychiatric treatment.
According to the review of the literature per-
formed by Issakidis and Andrews, 16–23% of
patients who receive over a year long therapy
of mental disorders terminate treatment ear-
ly. Furthermore, pre-treatment attrition (i.e.
attrition that occurs before the beginning of
the study (Hofmann 1998) seems to be a huge
problem too. Data gathered by the cited 
au thors hint that 30–50% of patients sched-
uled for treatment either fail to commence 
or do not complete treatment (Issakidis and
Andrews 2004).
According to Hummer’s and Fleischhacker’s
proposal, the reasons for non-compliance can
be divided into four groups. At least some of
those factors are modifiable.
The first group comprises patient-related
factors. Patients can be reluctant to adhere to
the treatment because of the psychopatholo-
gy of the anxiety disorder itself. For example,
high trait anxiety may lead to so-called ‘pas-
sive non-compliance’ – namely forgetting
about the medicines and irregular intake of
them. Being anxious of stigmatization and
rejection, as well as various dysfunctional
beliefs about the disorder and its treatment
(‘taking drugs is a weakness’, ‘drugs can be
addictive’, ‘by taking drugs I’m not myself
anymore’…), might further increase the risk
of non-compliance. Age can also be an impor-
tant confounder. Worse compliance among
elderly patients with anxiety disorders can be
implied by impaired memory or co-existing
medical illnesses, requiring intake of numer-
ous drugs. Finally, comorbid psychiatric dis-
orders – especially substance abuse – might
increase the rate of non-compliance. Such
compounds as alcohol or benzodiazepines can
be used by the patients as measures of ‘self-
treatment’.
The second group consists of environmental
or social factors. Patients’ families’ negative atti-
tude towards treatment, familial conflicts or dif-
ficult economic situation increase the risk of
non-compliance. On the other hand, such fea-
tures as effective social support networks and
lasting intimate relationships facilitate compli-
ance and adherence to treatment.
The third group consists of physician-relat-
ed factors. The ‘technical approach’ towards
the patient presented by the physician and the
healthcare professional’s lack of engagement
in the relationship may become a real obstacle
that decreases rates of compliance. However,
the patient’s belief that the physician is inter-
ested in him or her as ‘a human being who
happened to be a patient’, as well as the doc-
tor’s established conviction of effectiveness of
the concrete therapy, are all factors that
improve compliance.
The final group of factors consists of fea-
tures of the treatment itself. Side effects, dif-
ficulties with dosage and way of drug appli-
cation, length of treatment and using large
amounts of drugs at the same time are all ele-
ments that impede following the physician’s
instructions. Of note, severe side effects seem
to be – along with male gender and younger
age – risk factors of discontinuation only dur-
ing the initial five weeks of treatment. They
do not seem to influence compliance in the
further course of therapy. There are no data
suggesting that compliance rates of some
drugs are significantly different from compli-
ance rates of others (Hummer and Fleis-
chhacker 1999).
One of the most important factors influenc-
ing compliance rates in psychiatry is the fact
that psychiatric patients miss their appoint-
ments almost twice as frequently as patients
seeking help for somatic reasons. According to
data gathered by the UK Department of
Health, in 2002–2003, 19.1% of psychiatry
out-patients appointments were missed, while
the overall UK figure was only 11.7% (Depart-
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ment of Health, 2003). Key social and clinical
predictors of non-attendance (summarized by
Alex J. Mitchell and Thomas Selmes) are pre-
sented in Table 1. In their review, Mitchell and
Selmes have also collated a set of measures to
reduce the scale of this problem. The latter list
can be found in Table 2.
How compliant are patients with 
anxiety disorders?
Data on the compliance rate among patients
with anxiety disorders are relatively scarce and
– at times – contradictory. Issakidis and
Andrews argue that up to 50% of patients
belonging to this group are at risk of the most
severe form of non-compliance, namely a fail-
ure to commence or complete treatment
(Issakidis and Andrews 2004).
More optimistic conclusions derive from the
study performed by Koivumaa-Honkanen et al.,
who analysed various aspects of life satisfaction
and course of treatment among patients with
schizophrenia, major depression or anxiety dis-
orders. The authors divided compliance into
three dimensions, covering medication adher-
ence, as well as attending appointments and on-
call visits. In the group of anxiety disorders, the
medication compliance rate was 61.9%,
appointment compliance was as high as 97.8%,
and on-call visit compliance was the worst
(11.5%) (Koivumaa-Honkanen et al. 1999).
Those results seem to be in accordance with
everyday clinical experience, suggesting that
compliance among patients with anxiety disor-
ders is mostly satisfactory. Given the fact that
symptoms related to this group of psychiatric
disorders both cause significant distress and are
Compliance in anxiety disorders
Table 1. Key predictors of non-attendance among psychiatric patients (from Mitchell and Selmes 2007)
Environmental and demographic factors:
younger age, lower socio-economic status, not having health insurance (where healthcare is not free at point of delivery), 
poor adherence to psychotropic medications, homelessness, transport problems, distance from clinic
Patient factors:
forgetting, oversleeping, getting the date wrong, being too psychiatrically unwell, high trait anxiety, lower social 
desirability scores, dismissing attachment styles
Memory/cognitive problems:
dementia
Illness factors:
personality disorder, substance misuse (alone or in combination with other psychiatric disorder), neurotic disorders, 
diagnosis unclear or cannot be established
Clinician and referrer factors:
poor communication between the referring practitioner and the patient, patient’s disagreement with the referral, 
referrer’s scepticism about the value of psychiatry, poor-quality referral letter, longer delay between the referral 
and the appointment (or between assessment and treatment), early stages of treatment, quality of therapeutic alliance, 
non-collaborative decision-making
Table 2. Simple measures to reduce non-attendance among psychiatric patients (from Mitchell and Selmes 2007)
Improving initial attendance Improving follow-up attendance Response to missed appointments
• Encourage referrers to explain the
purpose of the referral.
• Schedule the appointment as soon
as possible.
• Write to the patient with clear direc-
tions and explaining the mechanism
of referral.
• Offer the option of an afternoon
appointment.
• Offer the option of a community/
home visit if the patient is too unwell
to attend.
• Consider a reminder telephone call
the day before the appointment 
(if the patient has a telephone).
• Give the patient a choice of appoint-
ment dates and/or locations. 
• Schedule the appointment as soon as
possible.
• Where possible, agree the duration of
the treatment course at the start.
• Work towards establishing and main-
taining a good therapeutic relationship.
• Involve the patient in treatment deci-
sions.
• Contact the patient by letter or tele-
phone.
• Identify any patient-cited barriers 
to attending.
• Confirm that the patient wishes to
attend.
• Affirm that the patient can still be seen
without prejudice.
• If possible convey hope that there 
is a definite prospect of improvement.
• Reschedule the missed appointment
as soon as possible.
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not burdened with social stigma, patients with
anxiety disorders are keen on searching for pro-
fessional help.
The study by Issakidis and Andrews (per-
formed in Australia) gives us an important
insight into sociodemographic and clinical char-
acteristics of patients who were reluctant to join
and/or continue therapy.
In general, 68.7% out of 731 patients with
anxiety disorders who were offered treatment
actually entered therapy and 61.6% complet-
ed the therapeutic cycle. The pre-treatment
attrition (i.e. active refusal and non-contact with
the clinic after initial assessment) rate was
30.4%. The most common ‘source’ of attrition
was non-attendance at pre-treatment interview,
or failure to re-contact the clinic to schedule the
treatment (17.8%). Active therapy refusal was
a little bit rarer (12.6%). On the other hand,
once patients commenced therapy, dropouts
were uncommon (10.3%).
One of the significant predictors of pre-treat-
ment attrition was primary diagnosis, especial-
ly among patients with depression or other
comorbidities. Furthermore, the more severe the
depression, the greater the attrition risk was
observed (this highlights the importance of an
in-depth assessment of depressive symptoms
among individuals with anxiety disorders). It
should be stressed that severity of anxiety symp-
toms does not seem to be related to the pre-
treatment attrition risk.
Given anxiety disorders only, the greatest risk
of attrition was noted among people with ago-
raphobia (39.8%), followed by generalized anx-
iety disorder (GAD) (34.0%), social anxiety dis-
order (SAD) (30.4%) and panic disorder (PD)
(27.9%). Nevertheless, the differences between
disorders were statistically insignificant. Inter-
estingly enough, presence of at least one child
was positively associated with probability of
treatment attrition. But if we take into account
the fact that this relationship was significant
only among women, it does not seem to be
strange anymore (in most societies of European
descent it is still true that women are more pre-
occupied with taking care of children than men,
so they are less likely to turn attention to their
own health at the cost of time spent with the
offspring). This risk-gender relationship was the
strongest among patients with agoraphobia, but
at the same time the proportion of women was
the highest in this same group (77.4%).
People who reported milder disorder-specif-
ic symptoms, as well as those patients who were
experiencing higher levels of physical impair-
ment, were of higher risk of dropping out of
treatment. It is possible that people who expe-
rience less impairment, as well as those individ-
uals who have benefited from the early stages of
therapy, may resign from the treatment early.
Of note, demographic, clinical and systemic
factors had a rather weak influence on the risk
of pre-treatment attrition and dropout. It would
be interesting to emphasize that people who
were referred by a general practitioner were less
devoted to therapy than those individuals who
were advised to join the treatment by a mental
health specialist.
The study by Issakidis and Andrews gives
further evidence that anxiety disorder therapy
delivered in a specialist clinic is burdened with
lower dropout risk than psychotherapy provid-
ed in an outpatient setting (as shown by com-
parison with the results of the meta-analysis
performed by Wierzbicki and Pekarik (1993).
The hypothesis that ‘the time-limited, struc-
tured, evidence-based nature of treatments
delivered in specialist clinics contributes to low
dropout rates in these settings’ (Issakidis and
Andrews 2004) has been supported by several
authors. For example, Sledge et al. reported that
people with anxiety and depressive disorders
who received an outpatient treatment were less
likely to give up therapy prematurely when pro-
vided with time-limited psychotherapy com-
pared with psychotherapy without a set time
limit (Sledge et al. 1990). Wierzbicki and
Pekarik suggest that patients’ expectations may
also contribute to this kind of outcome.
Finally, we should take note of the fact that
patients with anxiety disorders were more like-
ly to resign from the group cognitive-behav-
ioural therapy (CBT) rather than from the indi-
vidual therapeutic sessions. This may be
a reflection of the fact that people experiencing
anxiety tend to be reluctant to engage in social
situations (Issakidis and Andrews 2004).
The key results of the study by Issakidis and
Andrews are summarized in Table 3.
Impact of compliance on treatment
outcomes in anxiety disorders
There is a general scarcity of research data on
the interplay between therapeutic compliance
and outcomes of treatment of anxiety disorders.
Available sources allow us to assess this relation-
ship only for the two major therapeutic approach-
es towards the discussed class of psychiatric 
problems: cognitive-behavioural therapy and
pharmacotherapy with antidepressant drugs.
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Compliance with cognitive-behavioural
therapy
Cognitive behavioural therapy is the basic
psychotherapeutic approach to treatment of
anxiety disorders (Chodkiewicz and Mniszew -
ska 2006).
One of the most important assumptions of
CBT is the thesis that acquisition of new skills
and knowledge might exert a therapeutic
impact in patients with certain psychiatric dis-
orders (Chojnacka 2009). Those novel compe-
tences can be achieved only with the patient’s
active participation in regard to relevant treat-
ment-related assignments (often called ‘home-
works’) (Schmidt and Woolaway-Bickel 2000).
It means that the quality of the patient’s adher-
ence to the therapist’s instructions should be (in
theory at least) one of the major determinants
of the treatment outcome.
Panic disorder
In the case of panic disorder (PD), CBT pro-
tocols include acquisition of a number of skills,
including cognitive restructuring, interoceptive
exposure, breathing control procedures, educa-
tion, and in vivo therapy techniques (Wolfe and
Maser 1994, as cited in Schmidt and Wool-
away-Bickel 2000). Although it would be a tru-
ism to say that both quantity and quality of
homework count, things get more intriguing
when we ask whether all the elements of this
CBT scheme are equally effective in treatment
of PD. But first of all, what does ‘quality of
homework’ mean?
In an attempt to resolve this issues, Schmidt
and Wollaway-Bickel adopted the following
definitions:
• ‘The quantity compliance rating was the per-
centage of assigned homework that was com-
pleted (0–100%).’
• ‘The quality compliance rating was based on
the overall quality of the work conducted
during the previous week (0 = poor, 
1 = marginal, 2 = fair, 3 = good, 4 = very
good, 5 = excellent). […] For example, in
completing in vivo or interoceptive exposure
exercises, we considered five main criteria in
evaluating homework quality: a) whether
a specific task was identified, b) whether the
task generated moderate levels of fear, 
c) whether the task was repeated until fear
was extinguished, d) whether the patient
identified any “safety aids” (i.e., coping strate-
gies used to assist them in dealing with their
fear during exposure); and e) whether safety
aids were successfully faded during practice
and, in the case of interoceptive exposure,
whether the exercise produced a sufficiently
high level of sensation.
• ‘We considered four criteria in rating cogni-
tive restructuring exercises: a) whether an
anxiogenic cognition was appropriately iden-
tified, b) whether the patient evaluated the
evidence in support and against this thought,
c) whether an appropriate behavioural exper-
iment was developed in response to identi -
fication of an unrealistic thought, and 
d) whether the patient completed the behav-
ioural experiment’ (Schmidt and Woolaway-
Bickel 2000).
In the given research the overall ‘quantitative
compliance’ was moderately high, remaining in
the range between 55 and 65%. Quality ratings
were increasing over time. Opti mistically
enough, the outcomes were encouraging. Con-
sidering panic attacks, the recovery rate was
94%, in the case of anxiety 83%, and 71% for
phobic avoidance. Researchers have noted a sig-
Compliance in anxiety disorders
Table 3. Predictors of pre-treatment attrition and dropout of 
therapy among patients with anxiety disorders (from Issaki-
dis and Andrews 2004, modified)
Predictor variables OR 95% CI
Pre-treatment attrition
PD 1.0 –
agoraphobia 1.5 0.9–2.5
SAD 1.1 0.7–1.7
GAD 1.2 0.6–2.4
depression 4.0 1.6–10.0
other disorder 3.6 1.4–8.8
more depressed (DASS depression scale) 1.2 1.0–1.5
at least one child* 1.3 0.9–1.9
offered group vs. individual treatment 3.3 1.6–2.7
referred by a general practitioner vs. 1.6 1.1–2.3
mental health specialist
Dropouts
milder symptoms pre-treatment 1.8 1.2–2.7
(disorder specific)
more depressed (DASS depression scale) 2.0 1.4–2.9
more physically disabled (SF-12 physical 1.6 1.2–2.1
health scale)
female 2.4 1.1–5.4
*Only significant in interaction with primary diagnosis
CI – confidence interval, DASS – Depression Anxiety Stress Scales, 
GAD – generalized anxiety disorder, OR – odds ratio, PD – panic disor-
der, SAD – social anxiety disorder
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nificant relationship between therapist-rated
quality of compliance and clinical improvement.
Patient-rated compliance has not been related
to the outcome. The striking conclusion of this
study seems to be the fact that compliance with
particular skills has been associated with
changes in related symptom variables. For
example, compliance with therapeutic session
focused on completing in vivo exposure to
a phobic situation was a significant predictor of
change in phobic avoidance. Accordingly, com-
pliance with sessions linked to cognitive restruc-
turing led to a decrease in panic frequency and
intensity, as well as to a reduction of anticipa-
tory anxiety. Alleviation of fear of bodily 
sensations was associated with compliance with
sessions focused on interoceptive exposure
(Schmidt and Woolaway-Bickel 2000).
Obsessive-compulsive disorder
In the case of patients with obsessive-com-
pulsive disorder (OCD), so-called exposure and
response (ritual) prevention (EX/RP) is an estab-
lished therapeutic method (belonging to the arse-
nal of CBT techniques). The point of this tech-
nique is to gain new information and abilities to
modify dysfunctional thoughts and behaviours
rooted in OCD. Patients undergoing EX/RP
receive psychoeducation about OCD and are
repeatedly exposed to situations and stimuli that
provoke obsessions. They are also taught that
breaking the vicious circle of obsessions and com-
pulsion by refraining from compulsive rituals will
eventually lead to long-term relief (Abramowitz
et al. 2002). As this task is difficult for the major-
ity of people with OCD, one can assume that
patients’ reluctance to perform homework may
be the key obstacle in compliance.
Yet again there have been relatively few
attempts to determine the relationship between
compliance and outcomes of EX/RP. Moreover,
the results of the performed studies are incon-
sistent. According to O’Sullivan et al., higher
quality of compliance with EX/RP led to a re -
duction of the severity of rituals at six-year fol-
low-up (O’Sullivan et al. 1991), while Lax et al.
failed to find any relationship between those
variables (Lax et al. 1992). In a newer study,
Abramowitz et al. assessed this issue, having sin-
gled out four components of compliance (psy-
choeducation, i.e. understanding the treatment
rationale; in-session exposure; homework expo-
sure; and ritual prevention). They concluded
that severity of OCD and depressive symptoms
(patients with OCD and comorbid conditions
were enrolled in the study) were not related to
degree of compliance with EX/RP techniques.
This finding can be explained by the flexibility
of the method discussed (i.e. patients with more
severe OCD symptoms were given less difficult
tasks). Neither other psychiatric comorbidities
(major depressive disorder, bipolar disorder,
GAD, SAD or PD) nor pharmacotherapy influ-
enced the quality of adherence. The authors
found that various levels of compliance with
EX/RP were among the most important factors
affecting therapeutic outcomes, responsible for
64% of variance in post-treatment OCD sever-
ity. In detailed analysis they proved that ‘under-
standing the rationale for EX/RP, compliance
with in-session exposure and compliance with
homework exposure were strongly associated
with less severe post-treatment OCD symp-
toms’ (Abramowitz et al. 2002). Moreover, some
interrelationships between individual elements
of the EX/RP method were identified. As one
might expect, ‘Patients who evidenced greater
compliance with in-session exposure were also
more compliant with homework exposure
instructions. Also, patients who better under-
stood the rationale for EX/RP were more com-
pliant with in-session exposure instructions’
(Abramowitz et al. 2002). This finding empha-
sizes the importance of psychoeducation. Inter-
estingly enough, the impact of psychoeducation
on the treatment outcome can be interpreted
in two ways. On one hand, psychoeducation
may provide the patient with the insight that
makes is easier to cope with the challenges of
anxiety-evoking exposures. On the other, as the
psychoeducational process progresses through
EX/RP, patients who have already undergone
in-session exposures ‘come to better understand
the treatment rationale by the benefit of their
own experience with these procedures’
(Abramowitz et al. 2002).
Nevertheless, the effectiveness of EX/RP tech-
nique is far from optimal. Bonchek points out
three major difficulties related to this method.
First of all, only about half of the patients receiv-
ing this form of treatment improve. The rest are
burdened with relapses or various forms of non-
compliance (dropouts or non-adherence). The
second argument explaining frequent dropouts
of EX/RP refers to the fact that ‘the essence of
EX/RP is to have the person confront his com-
pulsion head on’ (Bonchek 2009). This strategy
might cause an unacceptable level of distress for
the patient. The third problem is that the
patients undergoing EX/RP are likely to obey
the rules of this therapy in the presence of the
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therapist rather than ‘in the privacy of their
homes’. Having considered all these obstacles,
Bonchek suggests that a suitable alternative to
EX/RP (overcoming the main limitations of this
method) is Strategic/Behavioral Treatment. 
The key assumption of this form of treatment is
that the patient’s compliance (obtained by –
among others – a positive, non-confrontational
therapeutic style) is the prerequisite of psy-
chotherapeutic effectiveness. So the first step on
the therapeutic path should be to reduce or elim-
inate the patient’s resistance (for details, see
Bonchek 2009).
Finally, we must emphasize that not only the
type of psychotherapeutic approach but also the
pattern of symptoms has an impact on the qual-
ity of compliance among patients with OCD
(although there are few data on this issue). It is
interesting to note that Mataix-Cols et al. have
shown that for the patients with hoarding
symptoms it may be more difficult to comply
with treatment. This finding can be interpret-
ed as a result of some specific clinical features
of this population: poor insight about their
problems, ego-syntonicity of their behaviour,
denial, rationalization and low motivation to
change (Mataix-Cols et al. 2002).
Social anxiety disorder
It seems that one of the most important fac-
tors determining the quality of compliance with
CBT (or – in a more general sense – therapeu-
tic alliance) among patients with SAD is their
difficulty in forming interpersonal relationships.
At the same time, it might be a necessary con-
dition implying a chance for therapeutic suc-
cess. Hayes points out that the distress related
to symptoms of social phobia may be strongly
involved in the psychotherapeutic setting itself
(Hayes 2007).
However, in this group of patients, the rela-
tionship between quality of compliance and
treatment outcome can be tricky. Although the
authors mentioned above confirmed the exis-
tence of an interrelation between client-rated
(but not observer-rated) therapeutic alliance and
session helpfulness (Hayes 2007), the results of
other studies are puzzling. Woody and Adessky
found that although strength of working
alliance increased in the course of therapy, this
statement was not related to treatment results
(Woody and Adessky 2002). VanDyke showed
that in spite of the fact that a strong therapeu-
tic alliance observed during the final CBT ses-
sion predicted decreased intensity of symptoms
at a follow-up, quality of alliance in the course
of earlier sessions did not seem to have anything
in common with treatment outcome. This
encourages an interpretation that these are
treatment gains that fuel therapeutic alliance –
not the opposite (VanDyke 2002, as cited in
Hayes 2007).
Several other aspects of compliance have also
been analysed among patients with SAD. There
is some evidence that homework compliance is
likely to have a positive impact on treatment
gains. Good therapeutic alliance also gives bet-
ter chances for the process of motivational inter-
viewing (in the case of individuals with poor
motivation for therapy). Motivational inter-
viewing may enhance the patient’s positive
expectancy for anxiety relief before treatment.
It may also contribute to better compliance with
CBT homework and, finally, to a better CBT
response (Pontoski 2009).
Generalized anxiety disorder
Huppert and Sanderson advocate psychoed-
ucation as the best way of enhancing compli-
ance among patients with GAD.
The cited authors attribute the paramount
importance to psychoeducation because they
‘believe that knowledge is an important factor
in change’. Many patients presenting with
symptoms of GAD have never been informed
about the disorder before, and multiple mis-
conceptions about GAD, as well as misunder-
standings about physiological or emotional
responses to worry, need to be clarified. Pro-
viding education about the biopsychosocial
model of anxiety may be the initial step of CBT
among this group of patients. Awareness of the
fact that their highly unpleasant experiences are
quite common might bring some relief by itself.
In terms of compliance, it seems that the most
important aspect of psychoeducation is that it
cast a shaft of light on the rationale of therapy.
Huppert and Sanderson recommend providing
psychoeducation ‘in a written form and then
followed up in session’ (Huppert and Sanderson
2009).
Compliance with pharmacotherapy
To the best of our knowledge, the most com-
prehensive study on the problem of compliance
in relation to pharmacotherapy among patients
with anxiety disorders (to date) is the one per-
formed by Stein et al., published in 2006. It is
no surprise that this publication seems to be the
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best of the very few available research findings
on this issue.
Stein et al. point out that adherence to treat-
ment with selective serotonin reuptake inhibitors
(SSRI) or serotonin norepinephrine reuptake
inhibitors (SNRI) is one of the major determi-
nants of therapeutic outcome among patients
with anxiety disorders. They also assume that
(analogically to depressive disorders) non-adher-
ence with medication in this population is asso-
ciated with substantial economic burden,
implied by patients’ inability to work, impair-
ment in social functioning and intensive utiliza-
tion of medical services (Stein 2006).
Having analysed 13 085 patients with vari-
ous anxiety disorders, the researchers found that
about 57% of people of that population were
deemed non-adherent at six months follow-up.
Interestingly enough, comorbid depressive and
anxiety disorders predicted a higher adherence
rate (47%) than ‘pure’ anxiety disorders (40%).
Moreover, patients with this pattern of comor-
bidity were more likely to change their med-
ication (40% vs. 25%) or have their dosage
titrated (58% vs. 43%). As in the study by
Issakidis and Andrews (see above), Stein et al.
also noted that patients who were treated by
a mental health specialist were more compliant
with antidepressant medications than those who
were seeking help from other medical special-
ists (respectively 50% and 44%).
Overall, compliance rates in the given popu-
lation were low. The authors emphasize that this
finding is yet further evidence for the unsatis-
factory quality of pharmacotherapy provided to
patients with anxiety disorders in primary care
(although adherence rates among people receiv-
ing treatment tailored by psychiatrists were
hardly any better). This is important, as current
anxiety disorder treatment guidelines advocate
prolonged therapy with SSRIs or SNRIs (Stein
2006). The fact that side effects (mainly drowsi-
ness or fatigue, followed by anxiety, headache
and nausea [Bull 2002]) are the most frequent
reason for discontinuation or switching SSRIs
leads us back to the idea of psychoeducation as
a crucial element of virtually all the psy-
chotherapeutic and psychopharmacotherapeu-
tic interventions. Providing the patient with
information about late onset of action of SSRIs
or SNRIs and possible side effects which might
occur during the initial weeks of therapy seems
to be the best way to improve compliance (Ban-
delow and Baldwin 2009). In this sense, disease
management programmes targeting (among
other problems) the issue of adherence (such as
collaborative care programmes for patients with
PD) may be beneficial (Stein 2006).
Conclusions
The view arising from the gathered data
strongly suggests that there is still much to be
done in the field of research on the importance
of treatment compliance in anxiety disorders.
For the time being there is relatively little evi-
dence strongly advocating the importance of
good compliance with regard to the treatment
outcomes of anxiety disorders en bloc. Prelimi-
nary data suggest that patients receiving psy-
chotherapy are more likely to be compliant with
treatment, probably due to the time-limited and
structured character of therapy delivered in spe-
cialist clinics. Furthermore, co-existence of
depressive disorders seems to be a positive prog-
nostic factor in terms of compliance (both with
psychotherapy and pharmacotherapy with anti-
depressant drugs).
Probably the most compelling evidence
regarding the relationship between compliance
and outcomes of psychotherapy are related to
CBT used in populations with panic disorder.
Furthermore, distinct elements of CBT tech-
nique seem to have a different impact on the
effectiveness of therapy. Data about OCD, SAD
and GAD are much less convincing. Most
authors argue that psychoeducation is the best
way of strengthening the quality of compliance
with the psychotherapy of anxiety disorders.
This research has not been aided by any grant.
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